Navigation Links
Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
Date:6/22/2013

tp://www.lillydiabetes.com/">www.lillydiabetes.com.

P-LLY
DIA568015PR

This press release contains forward-looking statements about empagliflozin* for the treatment of type 2 diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that empagliflozin* will receive regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

CONTACT:

Catherine London
Associate Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: usnews@boehringer-ingelheim.com
Phone: (203) 798-4638

Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: (317) 651-9116

References


  1. Barnett AH, et al. Empagliflozin in Patients with Type 2 Diabetes (T2DM) and Renal Impairment (RI). Poster No: 1104-P. Presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®. June 21-25, Chicago, IL.
  2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Center for Disease Control and Prevention, 2011.
  3. International Dia
    '/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
2. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
3. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
4. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
7. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
8. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
9. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
10. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
11. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... YORK , August 21, 2014 ... Israeli subsidiary, BreedIT Ltd., the exclusive worldwide license ... software for plant breeders and researchers, today is ... a joint venture with Seach Ltd, a leading ... formed to research and develop new breeds of ...
(Date:8/21/2014)... FAIRFAX, Va. , Aug. 21, 2014 /PRNewswire/ ... real-time quality and Manufacturing Intelligence , today ... Intelligence Conference. The event will be held Oct. ... Mile, and is designed to showcase the necessity ... use of metrics and Manufacturing Intelligence to gain ...
(Date:8/21/2014)... 21, 2014 CVS Caremark Corporation (NYSE: ... Yields and consideration payable in connection with its previously announced ... 2014 for (1) any and all of its 6.250% Senior ... up to a maximum amount of its 6.125% Senior Notes ... Notes due 2017 (collectively, the "Maximum Tender Offer Notes" and ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... Pharmaceuticals announced that Richard Kent, M.D., a partner at ... directors.  Dr. Kent will replace Garheng Kong, M.D., Ph.D., ... Kong, who has recently taken a position as a ... chairman of the board. Dr. Kent brings ...
... Reportlinker.com announces that a new market research ... Active Pharmaceutical Ingredients (APIs) Market to ... Sector will Sustain Growth ... Ingredients (APIs) Market to 2015 - Rise in ...
Cached Medicine Technology:Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors 2Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 2Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 3Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 4Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 5Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 6Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 7Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 8Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 9Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 10Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 11Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 12Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 13Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 14Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 15Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 16Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 17
(Date:8/21/2014)... chronic kidney disease patients may be a strong indicator ... in the Journal of the American Society of ... Hopkins Bloomberg School of Public Health assert that coronary ... atherosclerosis in predicting the risk of heart disease among ... all patients with chronic kidney disease (CKD) die from ...
(Date:8/21/2014)... Health System and The University of Texas MD Anderson ... a new level of specialized breast screening at a ... Houston area. , Starting in late November, MD Anderson ... services for five of Memorial Hermann,s 10 breast care ... and Sugar Land. , Over time, the network will ...
(Date:8/21/2014)... only is eating better and exercising healthy for people with ... year, a new study finds. The study, led by ... Forest Baptist Medical Center in Winston-Salem, N.C., included more ... Participants ranged in age from 45 to 76, ... program" focused on diet and exercise, or to a standard ...
(Date:8/21/2014)... August 21, 2014 Transvaginal mesh ... Inc. continue to move forward in the federal ... District of West Virginia, Bernstein Liebhard LLP reports. ... 14th, the Court has established new stipulated evidence ... handling, division, storage and preservation. (In re C.R. ...
(Date:8/21/2014)... FRANCISCO Aug. 21, 2014 Researchers in the ... congenital cataracts can quickly and accurately diagnose a number ... a study published online today in ... Ophthalmology. Using a single test, doctors were able ... on their mutations reducing the time and money spent ...
Breaking Medicine News(10 mins):Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:New DNA test for diagnosing diseases linked to childhood blindness 2
... People who suffer cardiac arrests and then receive coronary ... brain damage compared with those who don,t have the ... School of Medicine researchers. The study, published in the ... Medicine and now available online, showed that patient ...
... March 31 Responding to negative impacts on clinician productivity and ... Inc. ( www.usercentric.com ) - a ... service offering specifically for health care organizations (HCOs) : ... clinicians are struggling to adopt EHRs because they are too time-consuming ...
... Research (IADR) announces Dr. Anthony Fauci, director, National Institute ... Institutes of Health in Bethesda, Md., USA as 2009 ... at the 87th General Session & Exhibition in Miami, ... Dr. Fauci became director of NIAID, where he oversees ...
... of Cosmetic Surgery 2008 Procedural Survey shows a 2% ... the first time in several years, male cosmetic surgery ... of Cosmetic Surgery (AACS), a leader in the cosmetic ... survey reveals that males are cutting back on cosmetic ...
... The not-for-profit LENA Foundation is putting forth a ... Society of Research in Child Development (SRCD). At the ... one poster will be presented based on findings using ... SRCD is a great opportunity for our colleagues to ...
... FRAMINGHAM, Mass., March 31 Courion(R) Corporation ... today announced that Kurt Johnson, vice president of corporate ... leader of technical management, will deliver a presentation entitled ... Compliance," at the HIMSS 09 Annual Conference ...
Cached Medicine News:Health News:Coronary angiography may improve outcomes for cardiac arrest patients 2Health News:Coronary angiography may improve outcomes for cardiac arrest patients 3Health News:User Centric to Address EHR Usability With New Service Offering 2Health News:User Centric to Address EHR Usability With New Service Offering 3Health News:Male Cosmetic Surgery Slows Down While Female Cosmetic Surgery Advances 2Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 2Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 3Health News:Courion and Alegent Health to Discuss HIPAA and Next-Generation Healthcare Portals at HIMSS 09 Annual Conference and Exhibition 2
...
...
... antimony pH catheters are designed for patient comfort ... catheters are number marked at 5cm intervals and ... sixteen individual models are available spanning most clinical ... multi-use models with one or two sensors., ...
... designed for patient comfort as well as dependable ... at 5cm intervals and line marked each centimeter., ... available spanning most clinical needs and the range ... or two sensors., ,A range of four ...
Medicine Products: